Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux

Miriam Lee,*,** Petri T. Kovanen,1,* Gabriella Tedeschi,§ Emanuela Oungre,§ Guido Franceschini,† and Laura Calabresi†

Wihuri Research Institute,* Helsinki, Finland; Center E. Grossi Paoletti, Department of Pharmacological Sciences,1 Institute of Veterinary Physiology and Biochemistry,§ University of Milan, Italy; and Faculty of Biology,** University of Havana, Cuba

Abstract Mast cell chymase, a chymotrypsin-like neutral protease, can proteolyze HDL3. Here we studied the ability of rat and human chymase to proteolyze discoidal preβ-migrating reconstituted HDL particles (rHDLs) containing either apolipoprotein A-I (apoA-I) or apoA-II. Both chymases cleaved apoA-I in rHDL at identical sites, either at the N-terminus (Tyr18 or Phe33) or at the C-terminus (Phe225), so generating three major truncated polypeptides that remained bound to the rHDL. The cleavage sites were independent of the size of the rHDL particles, but small particles were more susceptible to degradation than bigger ones. Chymase-induced truncation of apoA-I yielded functionally compromised rHDL with reduced ability to promote cellular cholesterol efflux. In sharp contrast to apoA-I, apoA-II was resistant to degradation. However, when apoA-II was present in rHDL that also contained apoA-I, it was degraded by chymase. We conclude that chymase reduces the ability of apoA-I in discoidal rHDL particles to induce cholesterol efflux by cleaving off either its amino- or carboxy-terminal portion. This observation supports the concept that limited extracellular proteolysis of apoA-I is one pathophysiological mechanism leading to the generation and maintenance of foam cells in atherosclerotic lesions.—Lee, M., P. T. Kovanen, G. Tedeschi, E. Oungre, G. Franceschini, and L. Calabresi. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. J. Lipid Res. 2003. 44: 539–546.

Supplementary key words apoA-I proteolysis • mast cell chymase • reconstituted HDL

Chymases are neutral proteases whose specificity is chymotrypsin-like; peptide bonds are cleaved on the carbonyl side of a) aromatic residues with the order of preference Phe>Tyr>Trp, and b) the branched aliphatic amino acids Val, Ileu, and Leu (1). These enzymes are produced mainly or exclusively by mast cells, and are also found in mast cells of the human arterial intima, the site of atherogenesis (2). In atherosclerotic lesions, the mast cells are activated and release a fraction of their chymase-containing cytoplasmic secretory granules into their microenvironment, where chymase may act on extracellularly located substrates.

Chymase of rat serosal mast cells (rat mast cell protease I) has been found to inhibit cholesterol efflux from macrophage foam cells (3). This finding emerged from studies in vitro concerning the effect of exocytosed rat mast cell granule remnants (i.e., granule remnants) on the functional modification of HDL, and was the first to suggest that a neutral protease present in the arterial intima could block cholesterol transport from this tissue.

The early studies demonstrated that when HDL3 is incubated with the chymase-containing granule remnants derived from degranulating rat serosal mast cells, it is rapidly proteolyzed and that after even a minimal degree of proteolysis, the net efflux of cholesterol promoted by HDL3 from macrophage foam cells is significantly inhibited (3). In this in vitro system, degradation by granule remnant-bound chymase of the LpA-I particles present in HDL3 or in human plasma inhibited the high-affinity component of cholesterol efflux because of specific depletion of the minor subpopulation of preβ1-HDL particles (4, 5). Proteolysis of human plasma by granule remnant-bound chymase also depleted its contents of LpA-IV (5), another minor subpopulation of lipid-poor HDL that is responsible for the high-affinity efflux of cholesterol in apoA-I-deficient plasma (6).

Abbreviations: rHDL, reconstituted HDL; rh-chymase, recombinant human chymase.

† To whom correspondence should be addressed.

e-mail: petri.kovanen@wri.fi
Recently we demonstrated, using monoclonal site-specific apoA-I antibodies, that degradation of HDL₃ by granule remnant-bound chymase modified several epitopes of apoA-I that are involved in the efflux of cholesterol or in the activation of LCAT (7). Notably, after a minor degradation of HDL₃ with chymase, a truncated form of apoA-I (26 kDa) and small lipid-free peptides had been formed (7). These changes were paralleled by a rapid modification of the apoA-I epitope specific to preβ₂-HDL (8), and were accompanied by rapid loss of the ability of HDL₃ to act as a cellular cholesterol acceptor. Interestingly, the proteolytically modified HDL₃ retained its ability to induce cholesterol esterification via LCAT activation, suggesting a differential response to apoA-I proteolysis of the two main functions of HDL in reverse cholesterol transport.

The experimental approach of the above studies did not allow us to draw conclusions regarding the specific cleavage sites of apoA-I in the poorly lipidated preβ-migrating species of the HDL₃ fraction by chymase and its effect on their ability as cholesterol acceptors. Here, we performed further studies to characterize the digestion products associated with the chymase-induced modification of the cholesterol acceptor function of the major HDL apolipoproteins using a well-defined system of reconstituted HDL (rHDL) containing POPC and apoA-I or apoA-II as the sole apolipoprotein. These discoidal preβ-migrating rHDL particles are analogs of the precursors of the plasma α-migrating HDL, and have proven useful in studies on the relationships between the structure and function of HDL apolipoproteins and HDL subpopulations (9–11). We now extend the studies initially performed with rat chymase and compare the degradation patterns of apoA-I produced by chymase of rat or human origin. Thus, the present paper concerns: a) the cleavage sites produced by rat and human chymase on apoA-I or apoA-II contained in a homogeneous population of discoidal preβ-migrating rHDL, and b) the effect of chymase treatment on the cholesterol efflux efficiency of these particles.

MATERIALS AND METHODS

Animals

Adult male Wistar rats and female NMRI mice were purchased from the Viikki Laboratory Animal Center, University of Helsinki.

Rat chymase from mast cell granule remnants

Serafom mast cells were isolated from the peritoneal and pleural cavities of rats. Degranulation was induced with compound 48/80 (Sigma) and the exocytosed granules, i.e., granule remnants, were isolated from the released material by centrifugation as described (12). The quantity of granule remnants is expressed in terms of their total protein content or of their proteolytic activity with BTEE as substrate, as previously described (13). This isolation procedure enables chymase to remain bound to the heparin glycosaminoglycan chains of the granule remnants and so partially protects the chymase from inactivation in the presence of its physiologic inhibitors (14). Hence, granule remnants contain active rat chymase bound to the heparin proteoglycan matrix (heparin chains) of exocytosed granule remnants.

Recombinant human chymase

Recombinant human chymase (rh-chymase) (specific activity 80 BTEE U/μg) expressed in the baculovirus-insect cell system was provided by Teijin Ltd., Hino, Tokyo, Japan. The preparation was dissolved in a buffer containing 150 mM NaCl, 1 mM EDTA, and 5 mM Tris-HCl, pH 7.4, for the HDL degradation assay. The working preparation was stable at 4°C for one week, and was fully inactivated by 100 μg/ml of soybean trypsin inhibitor (SBTI) (Sigma).

Reconstituted HDL

ApoA-I and apoA-II were purified from human blood plasma, as previously described (11). Discoidal preβ-migrating rHDL containing POPC and apoA-I or apoA-II with a POPC-protein weight ratio of 2.5:1 were prepared by the cholate dialysis technique (15). In the final preparation, all the protein was incorporated into stable rHDL, with no lipid-free apolipoprotein remaining. rHDLs containing both apoA-I and apoA-II were obtained as described before (11). The size distribution of rHDL was examined by nondenaturing polyacrylamide gradient gel electrophoresis (16) on precast 8–25% polyacrylamide gels, using the Pharmacia Phast System (Amersham Pharmacia Bio-Tech). After Coomassie Blue staining, the gels were scanned with a BioRad scanner, and the size of the rHDL was calculated with Bio-Rad Multi-Analyt software using thyroglobulin (17.0 nm), apoferritin (12.2 nm), catalase (9.2 nm), lactate dehydrogenase (8.2 nm), and BSA (7.1 nm) as calibrating proteins. The characteristics of the reconstituted particles are summarized in Table 1. POPC liposomes were prepared by the same procedure used for the rHDL, but omitting the protein in the starting mixture. The number of apolipoprotein molecules per rHDL particle was determined by cross-linking with dimethylsuberimidate, as described before (9). The phospholipid content of rHDL was determined by an enzymatic method (17), while the protein concentration was measured by the method of Lowry (18), with BSA as standard.

To evaluate effect of particle size on degradation of apoA-I by chymase (Fig. 3), we prepared homogeneous rHDL containing apoA-I and POPC with diameters of 9.6 nm, 12.5 nm, or 17.0 nm containing 2, 3, or 4 apoA-I molecules per particle, respectively, by the cholate dialysis technique (15), as previously described (19).

Chemical modification and radioactive labeling of lipoproteins

Human LDL (d = 1.019–1.050) was isolated from fresh normolipidemic plasma by sequential ultracentrifugation, using KBr (20). LDL was acetylated (acytetyl-LDL) by repeated additions of acetic anhydride (21). Acetyl-LDL, radiolabeled by treatment with [3H]cholesterol linoleate ([1,2(3)H]cholesterol linolate, Amersham Pharmacia) dissolved in 10% dimethylsulfoxide (22), yielded preparations of [3H]cholesterol linolate bound to acetyl-LDL with specific activities ranging from 30 dpm/ng to 100 dpm/ng protein. [3H]apoA-I rHDL and [3H]apoA-II rHDL were prepared by labeling the protein component by the Bolton–

<table>
<thead>
<tr>
<th>Type of rHDL</th>
<th>Diameter (nm)</th>
<th>POPC:Protein</th>
<th>Molecules/Particle</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApoA-I rHDL</td>
<td>9.6 ± 0.2</td>
<td>2.15 ± 0.151</td>
<td>2</td>
</tr>
<tr>
<td>ApoA-II rHDL</td>
<td>10.0 ± 0.1</td>
<td>1.96 ± 0.121</td>
<td>4</td>
</tr>
</tbody>
</table>

rHDL, reconstituted HDL.
Proteolysis of rHDLs by granule remnant-bound chymase and rh-chymase

In the standard assay, apoA-I rHDL or apoA-II rHDL (1 mg/ml) was incubated at 37°C in 150 mM NaCl, 1 mM EDTA, pH 7.4, in the absence or presence of either granule remnant-bound chymase (30 μg/ml of granule remnant total protein) or rh-chymase (0.5 μg/ml), both equal to 40 BTEE U/ml, for different periods of time up to 6 h. After incubation, all the tubes were rapidly cooled down by placing them on ice. To remove the granule remnant-bound chymase from the reaction mixtures, the tubes were centrifuged at 4°C at 15,000 rpm for 5 min to sediment the remnants, and the chymase-free supernatants were collected. To fully inhibit rh-chymase, SBTI (final concentration 100 μg/ml) was added to the vials. The incubation mixtures were then subjected to structural and functional studies as described below.

Analysis of proteolytic products

The digestion products were analyzed by SDS-PAGE on 10–16% acrylamide gradient slab gels, using the Tris-tricine buffer system (24). After electrophoresis, the peptide bands in the gels were either visualized with Coomassie Blue or transferred electrophoretically to PVDF membranes. The membranes were then stained with Coomassie Blue, and the bands of interest were carefully cut from the membrane and subjected to automated sequence analysis on a pulsed-liquid sequencer (Applied Biosystems) equipped with a 120A Applied Biosystems PTH analyzer.

The molecular weights of the chymase-generated proteolytic fragments were determined by Flight-Mass Spectrometry (MALDI/TOF-MS) using a Vestec Lasertec MALDI-TOF instrument (Perspective) operating in a linear mode. Ions formed by a pulse UV laser beam (nitrogen laser, λ = 337 nm) were accelerated through 28 KV. The instrument was calibrated with bovine heart cytochrome c (MW = 12,327) and flagellin from Bacillus subtilis (MW = 32,626). The calibration proteins and the samples were dissolved in a solution of ferulic acid in 50% acetonitrile: 50% water with 0.1% trifluoroacetic acid to a final concentration of 50 pmol/μl.

Cholesterol efflux assay

Peritoneal cells were harvested from unstimulated mice in PBS containing 1 mg/ml BSA. The cells were recovered after centrifugation and resuspended in DMEM (GIBCO) with 100 U/ml penicillin and 100 μg/ml streptomycin (medium A) supplemented with 20% fetal calf serum, and plated into 24-well plates (Becton Dickinson Labware). After incubation at 37°C for 2 h in humidified CO2, nonadherent cells were removed. After washing with PBS, the adherent cells (macrophages) were loaded with [3H]cholesterol by incubation for 18 h in the presence of 20 μg/ml of [3H]cholesterol linoleate acetyl-LDL in medium A containing 20% fetal calf serum. After [3H]cholesterol loading, the macrophages were washed with PBS and then incubated with fresh medium A containing the cholesterol acceptors and the SBTI (100 μg/ml), as required. Efflux experiments were performed by adding to the [3H]cholesterol-loaded macrophage rHDLs in the concentrations described in the figure legends, or by adding POPC liposomes providing the same quantities of phospholipids as in the rHDL. After 4 h, the media were collected and centrifuged at 200 g for 5 min. The radioactivity in each supernatant was determined by liquid scintillation counting. Under the conditions used, [3H]cholesterol efflux was found to be linear for up to 4 h of incubation with the [3H]cholesterol-loaded macrophages.

RESULTS

Effect of proteolysis on the apolipoprotein components of rHDLs

Incubation of rHDL containing apoA-I with rh-chymase resulted in progressive proteolytic degradation of apoA-I, shown by the formation of TCA-soluble peptides (Fig. 1). In contrast, incubation of apoA-II with rh-chymase did not generate significant amounts of TCA-soluble material. When the two types of rHDL were incubated with the chymase contained in rat granule remnants, the degradation profiles, as determined by the production of TCA-soluble material, were identical to those observed with the human enzyme (not shown).

The cleavage products generated by digestion of the two rHDLs with either chymase were analyzed on SDS-PAGE. Incubation of apoA-I rHDL (Fig. 2, top panels) with rh-chymase for up to 6 h yielded two major bands (2 and 3), corresponding to polypeptides with apparent molecular weights of approximately 26 kDa and 24 kDa. A faint band 2 was visible at 30 min of incubation, and its intensity remained essentially the same over time. A faint band 3 appeared after 2 h of incubation, and at 6 h its intensity had become strong. The same pattern of apoA-I degradation was obtained when rHDLs were incubated with the rat chymase (Fig. 2, top panels). The extent of hydrolysis
of apoA-I at the different incubation times was determined by densitometric analysis of the SDS-PAGE. When incubated with rh-chymase, apoA-I was hydrolyzed by \( \sim 15\% \) at 30 min and by \( \sim 35\% \) at 6 h of incubation. In the presence of rat chymase, apoA-I was degraded by \( \sim 30\% \) after 30 min and by \( \sim 40\% \) after 6 h of incubation. In contrast to apoA-I, the apoA-II in rHDL remained intact upon incubation with either chymase for up to 6 h (middle panels). However, when apoA-I was also present in the rHDL (A-I:A-II rHDL), apoA-II, in addition to apoA-I, was degraded by either chymase (results obtained with rh-chymase are shown in Fig. 2, bottom panel). Densitometric analysis revealed that apoA-II was hydrolyzed by about \( 15\% \) during the 6 h of incubation with either chymase.

Particle integrity over the time course of digestion with chymase was assessed by nondenaturing gradient gel electrophoresis (not shown). No changes in rHDL particle size were detected in control incubations without chymase. ApoA-I rHDL, consisting of a major species with a diameter of 9.6 nm and a minor component of 7.8 nm, did not change in size during the 6 h incubation, despite the extensive degree of protein degradation. No changes were observed in the size of the apoA-II rHDL, which consisted mainly of particles with a diameter of 10.0 nm, or in the size of the A-I:A-II rHDL particles (10.0 nm). No major free polypeptide was found in any preparation.

Effect of rHDL size on apoA-I degradation by chymase

To evaluate the effect of particle size on the efficiency of degradation of apoA-I by chymase, three homogeneous apoA-I rHDL particles were prepared. The three rHDLs had diameters of 9.6 nm, 12.5 nm, and 17.0 nm, and contained 2, 3, and 4 apoA-I molecules, respectively. When the three rHDL particles were treated with chymase, the same degradation pattern of apoA-I was observed; however, the extent of degradation varied between the three particles, such that apoA-I in the 9.6 nm particles was digested to a greater extent than apoA-I in the 12.5 nm or 17.0 nm particles (Fig. 3).

Cholesterol efflux promoted by untreated rHDLs and by rHDLs treated with rh-chymase or with granule remnant chymase

As expected (9), untreated rHDLs caused dose-dependent release of \(^{3}H\)cholesterol from mouse macrophage foam cell cultures. The addition of increasing concentrations of either apoA-I rHDL or apoA-II rHDL to \(^{3}H\)cholesterol-loaded macrophages resulted in a steep rise in the release of \(^{3}H\)cholesterol from the cells, up to about 25 \(\mu g/ml\); at higher concentrations, the efflux continued to increase, but less steeply. Over the entire concentration range, rHDLs containing apoA-II were able to induce the release of cell cholesterol more efficiently than the apoA-I-containing rHDLs. Addition of increasing concentrations of protein-free POPC liposomes, providing the same amount of phospholipids as were present in the rHDL preparations, led to only a moderate promotion of cell cholesterol efflux (not shown).

Pretreatment of apoA-I rHDL with rh-chymase or with granule remnant-bound chymase at 37\(^\circ\)C for different time periods up to 6 h resulted in progressive reduction of cholesterol efflux into the medium (Fig. 4, top panel). The inhibitory effect of the two enzymes was similar, a near-maximal effect (about 20\% reduction) being observed after 2 h of preincubation. In contrast, apoA-II
rHDL-mediated cholesterol efflux was not inhibited by either chymase (Fig. 4, bottom panel).

In agreement with the above results, investigation of the concentration dependence of cholesterol efflux promoted by apoA-I rHDL (Fig. 5, top panel) indicated that pretreatment of apoA-I rHDL with granule remnant-bound chymase or with rh-chymase for 2 h reduced their ability to act as cholesterol acceptors by about 20% at the maximal concentration of the acceptor, and again no difference was observed between the two chymases. The residual cholesterol efflux was still 2-fold higher than the efflux promoted by protein-free POPC liposomes, revealing that the partial proteolysis of apoA-I in the liposomes did not completely abolish the apoA-I-dependent stimulation of cholesterol efflux by the apoA-I rHDL. Preincubation of protein-free POPC liposomes with either chymase did not affect the cholesterol efflux induced by the liposomes (not shown). In contrast to the strong inhibitory effect of chymase on apoA-I rHDL function, preincubation of apoA-II rHDL for 2 h with either chymase failed to produce any significant changes in the cellular efflux of cholesterol (Fig. 5, bottom panel).

Identification of cleavage sites

The cleavage sites in apoA-I were identified after incubation for 2 h of apoA-I rHDL with either type of chymase by i) N-terminal sequencing of proteolytic fragments isolated by SDS-PAGE, and ii) determination of the molecular mass of the digestion products by mass spectrometry (Table 2). The incubation time was selected according to the previous results, which showed that the maximal effect in the chymase-dependent inhibition of the cholesterol efflux could be achieved after 2 h of incubation with either chymase. Sequence and molecular mass analyses indicated that band 2 in the SDS-PAGE gel included two distinct polypeptides, with molecular masses of 26 kDa and 25.98 kDa, their N-terminal sequences starting at Asp1 and Val19, respectively (Table 2). Therefore, band 2 contains two polypepti-
TABLE 2. Identity of fragments obtained by proteolysis of apoA-I rHDL

<table>
<thead>
<tr>
<th>SDS-PAGE Band</th>
<th>Molecular Mass</th>
<th>N-Terminal Sequence</th>
<th>Fragment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>28.08</td>
<td>Asp-Glu-Pro-Pro...</td>
<td>Asp&lt;sup&gt;1&lt;/sup&gt;-Glu&lt;sup&gt;293&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>26.00</td>
<td>Asp-Glu-Pro-Pro...</td>
<td>Asp&lt;sup&gt;1&lt;/sup&gt;-Phe&lt;sup&gt;225&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>25.98</td>
<td>Val-Asp-Val-Leu...</td>
<td>Val&lt;sup&gt;195&lt;/sup&gt;Glu&lt;sup&gt;293&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>24.27</td>
<td>Glu-Gly-Ser-Ala...</td>
<td>Glu&lt;sup&gt;125&lt;/sup&gt;-Glu&lt;sup&gt;221&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

* Labels of fragments refer to their corresponding band positions on SDS-PAGE (at the 2 h-time point), which can be found in Fig. 2. In cases where more than one sequence is present, comigration of fragments is assumed to be due to nonoptimal resolution on SDS-PAGE.

DISCUSSION

The present results demonstrate that (i) apoA-I in rHDL is susceptible to proteolysis by chymase, whereas apoA-II is not, unless the rHDLs also contain apoA-I; (ii) digestion of apoA-I by chymase is distinct from that reported for other proteases, and independent of the phospholipid:apoA-I ratio of the particles; and (iii) proteolysis of apoA-I by chymase reduces the ability of apoA-I rHDL to promote cholesterol efflux from cholesterol-loaded macrophages.

Previous studies have shown that apoA-I in preβ-HDL (25) or in discoidal rHDL (26) is susceptible to digestion by a variety of proteolytic enzymes, including trypsin and chymotrypsin. Various proteases that are found in the arterial intima, such as elastase (25-27), some metalloproteases (28), plasmin, and plasma kallikrein (25, 29) can also proteolyze apoA-I in preβ-HDL. Here we show that human chymase cleaves apoA-I in discoidal preβ-migrating rHDL and generates a proteolytic pattern identical to that produced by rat chymase, supporting the reliability of the rat mast cell granule remnant chymase as a physiological model that mimics apoA-I proteolysis by the human mast cell counterpart.

While apoA-II in plasma HDL is sensitive to proteolytic degradation by rat chymase, trypsin, and elastase (4, 27, 30), it differs from apoA-I in its susceptibility to digestion by the various metalloproteases. Stromelysin degrades almost all of the apoA-I without causing any apparent change in apoA-II, whereas the 92 kDa gelatinase appears to degrade apoA-II only (28). The present results with rHDL containing either apoA-I or apoA-II as a single protein component show that chymase clearly distinguishes between apoA-I, which is degraded, and apoA-II, which is completely resistant to proteolytic digestion by the enzyme. However, when apoA-II is present in rHDL, particles containing apoA-I also, it is degraded by chymase, likely reflecting changes in apoA-II conformation in the A-I:A-II rHDL, which expose potential sites of cleavage that are buried in the apoA-II rHDL.

Digestion of apoA-I rHDL by chymase generated three major proteolytic fragments; one cleavage site is located in the carboxy-terminal portion of apoA-I (Phe<sup>225</sup>), the other two are in the N-terminal region (Tyr<sup>18</sup> and Phe<sup>35</sup>). Interestingly, no major fragment corresponding to the size of a double-truncated apoA-I (cleavage at both ends) was formed. This proteolytic pattern is rather unique, as compared with other proteases, and it is independent of the rHDL particle size. A remarkable sensitivity to proteolysis of the central to C-terminal portion of apoA-I, from residue 100 down to the C-terminal end of the protein, has been established in several studies with different proteases (26, 28, 31). This portion of the lipid-bound molecule is arranged in a series of amphipathic α-helices interrupted by surface loops (32), which may be particularly accessible to the protease because of lack of an organized secondary structure (33). In contrast, the structure of the N-terminal region of apoA-I represents a distinct domain having a more globular conformation (34) and tight protein-protein interactions (35). This may explain the more limited susceptibility of this region to proteolytic digestion. In the present study, we show that human and rat chymases uniquely cleave apoA-I either at the carboxy or amino termini. By contrast, treatment of these same apoA-I-containing rHDLs with trypsin, chymotrypsin, or elastase left the amino terminal 119 residues of the protein intact (9). The unique cleavage sites of chymase at the N-terminus of apoA-I suggest that in this region the sites recognized by chymase are more exposed than those recognized by other proteases, or that the interaction between chymase and apoA-I is different from that of other proteases, allowing protein degradation. Interestingly, a recent paper (36) showed that macrophage metalloproteinases also could degrade apoA-I at both the N- and C-termini, and that the N-terminus cleavage is at residue 18, a cleavage site also observed with chymase.

The chymase-digested rHDLs containing apoA-I were less efficient in promoting cholesterol efflux from cholesterol-loaded macrophages than the nonproteolyzed apoA-I rHDL particles. This behavior of the apoA-I rHDL contrasted sharply with the apoA-II rHDLs, which were fully resistant to the proteolytic action of chymase and, consequently, retained their full capacity to induce cholesterol efflux even after chymase treatment. Since the size of rHDLs is known to affect their capacity for cell cholesterol uptake (10), we tested for the effect of chymase on the size of apoA-I rHDL. However, we found that chymase treatment did not modify the size of apoA-I rHDL particles, which indicates that the reduced efficiency of apoA-I rHDL for cell cholesterol efflux must have been due solely to apoA-I digestion. Therefore, it is likely that the portions of apoA-I cleaved by chymase are involved in the interaction of the apoA-I rHDL discs with the cell membrane structures participating in the regulation of cholesterol efflux.
Efflux of cellular cholesterol is considered to occur via two distinct pathways: i) interaction between lipid-free apoA-I and specific sites on the cell surface, with membrane microsolvilubilization and generation of small preβ-migrating HDL; and ii) a relatively nonspecific interaction of lipidated apoA-I, particularly of small HDL particles, with the cell, and diffusion of cholesterol from the cell membrane into the particle surface. The first pathway appears to be mediated by the ATP binding cassette transporter (ABCA1) (37), and the second may involve the scavenger receptor class B, type I (SR-B1) (38). The role of distinct apoA-I domains in cellular cholesterol efflux mediated by either lipid-free or lipidated apoA-I has been addressed by using monoclonal antibodies against epitopes distributed along the entire apoA-I sequence, and by using natural or recombinant apoA-I mutants (39-46). Taken together, earlier results suggest that sequences in the central (39-42) and C-terminal (43, 44, 47) regions of apoA-I may facilitate cholesterol efflux to lipidated apoA-I by interacting with specific lipid domains, or proteins in the cell membrane.

In view of the important role of the last apoA-I residues in facilitating cell cholesterol efflux, the cleavage of the extreme C-terminal portion (from Phe225) by chymase could by itself explain the reduced cell cholesterol uptake by chymase-treated native or reconstituted HDL. The effect of cleavage in the N-terminal portion of apoA-I is less clear. However, cleavage of both the N- and C-terminal portions of apoA-I has been found to be necessary for binding of rHDL to SR-BI (48). Our results show that incubation of rHDL up to 2 h with either type of chymase reduced the efflux of cell cholesterol (Fig. 4), and that this reduction in the efflux corresponded to the appearance of a single band in the SDS-PAGE gel (band 2). Notably, this band contained two digestion products of almost identical MW, which were formed by removal either of the first 18 (Tyr18) or the last 18 (Phe225) residues of apoA-I (Fig. 2, band 2; Table 2), and so precludes any conclusions about an independent role of the N-terminal or C-terminal cleavage sites of chymase in the promotion of cholesterol efflux.

In conclusion, the present data show that mast cell chymase proteolyzes apoA-I, but not apoA-II, in rHDLs when apoA-II is the only apolipoprotein present in rHDL. In contrast, when apoA-I was also present in the rHDL, resembling more the HDL particles found in plasma, apoA-II was also degraded. High degree of cleavage specificity of apoA-I by the rat and human chymase found here, i.e., only one cleavage at the C terminus and two cleavages at the N-terminus, adds this enzyme to the small group of physiologically neutral proteases that are found in plasma or in extracellular fluids and can be used as tools in the analysis of the structure and function of lipid-bound apoA-I.

More importantly, chymase digestion reduces the ability of apoA-I in small nonmature HDL particles to promote cholesterol efflux from macrophage foam cells. Such lipid-poor particles with preβ-mobility turn over very rapidly (49). Therefore, for chymase to have an impact on the preβ-dependent efflux of cellular lipids, the enzyme must also degrade the particles rapidly. Exocytotic secretion of chymase by degranulating mast cells occurs within seconds (2), and both depletion of preβ particles and impairment of cholesterol efflux by chymase are apparent within minutes in vitro (3, 5, 7). Since degranulated chymase-containing mast cells have been observed in human atherosclerotic lesions (50), our findings afford further support for the proposed role of degranulated mast cells in the inhibition of the initial steps of reverse cholesterol transport in vivo. The above observations also provide support for the more general concept that extracellular proteolytic degradation of apoA-I is one pathophysiologic mechanism leading to the generation and maintenance of foam cells in atherosclerotic lesions.

The authors thank the Teijin Ltd Company, Japan, for providing the recombinant chymase, and Mrs. Päivi Ihamuotila for excellent technical assistance. This study was supported by grants from the Paavo Nurmi Foundation and the Sigrid Jusélius Foundation to M.L. This study was also supported by grant No QLRI-1999-10070 from the European Union to P.T.K.

REFERENCES

27. Byrne, R. E., D. Polacek, J. L. Gordon, and A. M. Scanu. 1984. The enzyme that cleaves apolipoprotein A-I upon intracellular degradation of human plasma high-density lipoprotein-3 with blood polymer-
   hydrolyze high density lipoprotein. Unique disposition of apolipoprotein A-I increases susceptibility to pro-
29. Liadaki, K. N., T. Liu, S. Xu, B. Y. Ishida, P. N. Duchateaux, J. P. Kieger, J. Kane, M. Kriejer, and V. I. Zannis. 2000. Binding of high density (HDL) and discolored reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and apoA-I mutations on receptor binding. 
   derived cholesterol into preβ-migrating high density lipoproteins. 